A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. We are a leader in targeted protein degradation (TPD), a next-generation small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 79M | - | 73M |
| Net Income | -311M | -311M | -224M | -147M | -155M | -100M |
| EPS | $-3.69 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
| Free Cash Flow | -234M | -234M | -207M | -137M | -156M | -131M |
| ROIC | -21.1% | -25.7% | -26.7% | -37.1% | -31.5% | -21.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.05 | 0.05 | 0.01 | 0.22 | 0.04 | 0.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -349M | -349M | -262M | -166M | -161M | -101M |
| Operating Margin | 0.0% | - | - | -210.6% | - | -138.0% |
| ROE | -19.7% | -25.8% | -26.8% | -37.2% | -31.6% | -21.8% |
| Shares Outstanding | 84M | 84M | 75M | 58M | 54M | 48M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | N/A | 34M | 73M | N/A | 79M | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 37M | 62M | 137M | 164M | 189M | 240M | 317M | 317M |
| SG&A | 8.0M | 18M | 36M | 44M | 55M | 64M | 68M | 68M |
| EBIT | -42M | -46M | -101M | -161M | -166M | -262M | -349M | -349M |
| Op. Margin | N/A | -136.1% | -138.0% | N/A | -210.6% | N/A | N/A | 0.0% |
| Net Income | -41M | -55M | -100M | -155M | -147M | -224M | -311M | -311M |
| Net Margin | N/A | -160.6% | -137.6% | N/A | -187.0% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 4.9M | 3.9M | 3.9M |
| Returns on Capital | ||||||||
| ROIC | -36.2% | -19.2% | -21.7% | -31.5% | -37.1% | -26.7% | -25.7% | -21.1% |
| ROE | N/A | -19.2% | -21.8% | -31.6% | -37.2% | -26.8% | -25.8% | -19.7% |
| ROA | -35.3% | -11.2% | -16.5% | -25.7% | -25.5% | -22.9% | -22.9% | -17.9% |
| Cash Flow | ||||||||
| Op. Cash Flow | 18M | 88M | -129M | -153M | -103M | -195M | -233M | -233M |
| Free Cash Flow | 17M | 79M | -131M | -156M | -137M | -207M | -234M | -234M |
| Owner Earnings | 16M | 81M | -156M | -192M | -150M | -257M | -301M | -301M |
| CapEx | 532K | 9.1M | 1.6M | 2.8M | 34M | 13M | 1.4M | 1.4M |
| Maint. CapEx | 825K | 1.8M | 2.4M | 3.0M | 3.6M | 7.4M | 8.3M | 8.3M |
| Growth CapEx | 0 | 7.3M | 0 | 0 | 31M | 5.5M | 0 | 0 |
| D&A | 825K | 1.8M | 2.4M | 3.0M | 3.6M | 7.4M | 8.3M | 8.3M |
| CapEx/OCF | N/A | 10.3% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.2M | 5.2M | 25M | 35M | 43M | 55M | 60M | 60M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -70M | -278M | -423M | -388M | -289M | -483M | -764M | -273M |
| Cash & Equiv. | 76M | 31M | 48M | 68M | 110M | 120M | 357M | 357M |
| Long-Term Debt | 1.2M | 604K | 1.1M | 1.2M | 1.3M | 2.2M | 1.5M | 1.5M |
| Debt/Equity | -0.29 | 0.07 | 0.04 | 0.04 | 0.22 | 0.01 | 0.05 | 0.05 |
| Interest Coverage | -917.5 | -402.6 | -636.3 | -900.9 | -1021.8 | -50.6 | -82.7 | -82.7 |
| Equity | -74M | 284M | 460M | 490M | 395M | 836M | 1.6B | 1.6B |
| Total Assets | 117M | 487M | 606M | 603M | 576M | 978M | 1.7B | 1.7B |
| Total Liabilities | 82M | 203M | 146M | 113M | 181M | 142M | 163M | 163M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -76M | -129M | -229M | -384M | -531M | -755M | -1.1B | -1.1B |
| Working Capital | 58M | 192M | 359M | 348M | 320M | 443M | 788M | 788M |
| Current Assets | 93M | 302M | 451M | 419M | 405M | 510M | 871M | 871M |
| Current Liabilities | 35M | 111M | 93M | 71M | 86M | 68M | 83M | 83M |
| Per Share Data | ||||||||
| EPS | -24.28 | -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | -3.69 |
| Owner EPS | 0.35 | 1.57 | -3.26 | -3.55 | -2.56 | -3.42 | -3.57 | -3.57 |
| Book Value | -1.66 | 5.49 | 9.59 | 9.09 | 6.77 | 11.12 | 18.72 | 18.72 |
| Cash Flow/Share | 0.40 | 1.70 | -2.69 | -2.84 | -1.76 | -2.59 | -2.76 | -3.59 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 44.8M | 51.7M | 48.0M | 53.9M | 58.3M | 75.1M | 84.4M | 84.4M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -24.0 |
| P/FCF | N/A | 57.5 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 16.0 | 6.5 | 2.7 | 4.0 | 3.6 | 4.3 | 4.7 |
| Price/Sales | N/A | 64.3 | 36.3 | N/A | 18.3 | N/A | N/A | N/A |
| FCF Yield | N/A | 1.7% | -4.4% | -11.8% | -8.8% | -6.9% | -3.4% | -3.1% |
| Market Cap | N/A | 4.5B | 3.0B | 1.3B | 1.6B | 3.0B | 6.9B | 7.5B |
| Avg. Price | N/A | 42.35 | 55.14 | 30.18 | 24.68 | 39.95 | 45.68 | 88.53 |
| Year-End Price | N/A | 87.83 | 62.56 | 24.48 | 26.82 | 40.11 | 81.32 | 88.53 |
Kymera Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -10.3%.
Kymera Therapeutics, Inc. (KYMR) has a 5-year average return on invested capital (ROIC) of -28.6%. This is below average and may indicate limited pricing power.
Kymera Therapeutics, Inc. (KYMR) has a market capitalization of $7.5B. It is classified as a mid-cap stock.
Kymera Therapeutics, Inc. (KYMR) does not currently pay a regular dividend.
Kymera Therapeutics, Inc. (KYMR) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Kymera Therapeutics, Inc. (KYMR) generated $-234 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kymera Therapeutics, Inc. (KYMR) has a debt-to-equity ratio of 0.05. This indicates a conservatively financed balance sheet.
Kymera Therapeutics, Inc. (KYMR) reported earnings per share (EPS) of $-3.69 in its most recent fiscal year.
Kymera Therapeutics, Inc. (KYMR) has a return on equity (ROE) of -25.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 7 years of financial data for Kymera Therapeutics, Inc. (KYMR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kymera Therapeutics, Inc. (KYMR) has a book value per share of $18.72, based on its most recent annual SEC filing.